Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
ad [2017/06/18 16:45]
sflitman [Alzheimer's Disease and Mild Cognitive Impairment]
ad [2018/11/18 10:50]
sflitman [Alzheimer's Disease and Mild Cognitive Impairment]
Line 4: Line 4:
  
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^
-Mild Cognitive Impairment ​and Mild AD | Intravenous anti-amyloid ​antibody ​ |  III  |  Yes  |  33%  |  18 months ​ |  5 years  | +MCI and Mild AD | Intravenous anti-tau antibody ​ |  III  |  Yes  |  33%  |  18 months ​ |  5 years  | 
-| Mild AD | Oral BACE inhibitor |  III  |  Yes  |  50%  |  48 weeks  |  1+ years  | +MCI and Mild AD | Oral BACE inhibitor |  III  |  Yes  |  50%  |  48 weeks  |  1+ years  | 
-| Mild AD | Oral BACE inhibitor ​|  III  |  Yes  |  50%  |  ​48 weeks  |  ​1+ years  |+MCI and Mild AD | Counterpulsation device |  III  |  Yes  |  50%  | 24 weeks  |  1 year  | 
 +| Agitation in AD | Oral 5HT2A antagonist ​|  III  |  Yes  |  50%  |  ​weeks  |  ​None  | 
 +| Agitation in AD | Oral combination of two approved drugs |  III  |  Yes  |  33%  |  5 weeks  |  None  ​| ​
  
 Also see [[imaging|Imaging]]. Also see [[imaging|Imaging]].
Print/export
QR Code
QR Code ad (generated for current page)